Share on StockTwits

Research analysts at Gabelli began coverage on shares of Cubist Pharmaceuticals (NASDAQ:CBST) in a report released on Friday. The firm set a “buy” rating on the stock.

Cubist Pharmaceuticals (NASDAQ:CBST) opened at 68.55 on Friday. Cubist Pharmaceuticals has a 1-year low of $48.23 and a 1-year high of $82.12. The stock’s 50-day moving average is $68.1 and its 200-day moving average is $70.42. The company’s market cap is $5.162 billion.

Cubist Pharmaceuticals (NASDAQ:CBST) last issued its quarterly earnings data on Tuesday, April 22nd. The company reported $0.30 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by $0.03. The company had revenue of $261.20 million for the quarter, compared to the consensus estimate of $285.24 million. During the same quarter in the previous year, the company posted $0.34 earnings per share. The company’s revenue for the quarter was up 13.6% on a year-over-year basis. On average, analysts predict that Cubist Pharmaceuticals will post $0.58 earnings per share for the current fiscal year.

A number of other analysts have also recently weighed in on CBST. Analysts at Zacks reiterated a “neutral” rating on shares of Cubist Pharmaceuticals in a research note on Thursday. They now have a $72.00 price target on the stock. Separately, analysts at Ned Davis Research upgraded shares of Cubist Pharmaceuticals from a “sell” rating to a “neutral” rating in a research note on Monday, April 28th. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $75.21.

Cubist Pharmaceuticals, Inc (NASDAQ:CBST) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.